Flu season in the US: FDA approves first mRNA vaccine after a year with 32 million cases and 24,000 deaths

The United States Food and Drug Administration (FDA) has approved the first mRNA-based influenza vaccine for the upcoming flu season. This development arrives as the country faces significant annual health challenges, with recent data reporting 32 million cases of influenza and 24,000 associated deaths over the previous year.

This approval marks a shift in the standard options available to the public as the northern hemisphere enters the autumn season. The introduction of mRNA technology for the flu vaccine represents a new approach to managing the annual virus, which historically requires millions of Americans to decide on vaccination each year.